These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 37996748)

  • 1. 'Treasure trove' of new CRISPR systems holds promise for genome editing.
    Reardon S
    Nature; 2023 Dec; 624(7990):17-18. PubMed ID: 37996748
    [No Abstract]   [Full Text] [Related]  

  • 2. The Implications of CRISPR-Cas9 Genome Editing for IR.
    Perkons NR; Sheth R; Ackerman D; Chen J; Saleh K; Hunt SJ; Nadolski GJ; Shi J; Gade TP
    J Vasc Interv Radiol; 2018 Sep; 29(9):1264-1267.e1. PubMed ID: 30146193
    [No Abstract]   [Full Text] [Related]  

  • 3. CRISPR-Cas12 and Cas13: the lesser known siblings of CRISPR-Cas9.
    Yan F; Wang W; Zhang J
    Cell Biol Toxicol; 2019 Dec; 35(6):489-492. PubMed ID: 31468291
    [No Abstract]   [Full Text] [Related]  

  • 4. The Future of Multiplexed Eukaryotic Genome Engineering.
    Thompson DB; Aboulhouda S; Hysolli E; Smith CJ; Wang S; Castanon O; Church GM
    ACS Chem Biol; 2018 Feb; 13(2):313-325. PubMed ID: 29241002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diversity and evolution of class 2 CRISPR-Cas systems.
    Shmakov S; Smargon A; Scott D; Cox D; Pyzocha N; Yan W; Abudayyeh OO; Gootenberg JS; Makarova KS; Wolf YI; Severinov K; Zhang F; Koonin EV
    Nat Rev Microbiol; 2017 Mar; 15(3):169-182. PubMed ID: 28111461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing type I-F CRISPR-Cas system as a transcriptional activation tool in human cells.
    Chen Y; Liu J; Zhi S; Zheng Q; Ma W; Huang J; Liu Y; Liu D; Liang P; Songyang Z
    Nat Commun; 2020 Jun; 11(1):3136. PubMed ID: 32561716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo CRISPR editing with no detectable genome-wide off-target mutations.
    Akcakaya P; Bobbin ML; Guo JA; Malagon-Lopez J; Clement K; Garcia SP; Fellows MD; Porritt MJ; Firth MA; Carreras A; Baccega T; Seeliger F; Bjursell M; Tsai SQ; Nguyen NT; Nitsch R; Mayr LM; Pinello L; Bohlooly-Y M; Aryee MJ; Maresca M; Joung JK
    Nature; 2018 Sep; 561(7723):416-419. PubMed ID: 30209390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Toolkit of CRISPR-Based Genome Editing Systems in Drosophila.
    Xu J; Ren X; Sun J; Wang X; Qiao HH; Xu BW; Liu LP; Ni JQ
    J Genet Genomics; 2015 Apr; 42(4):141-9. PubMed ID: 25953352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying Novel Enhancer Elements with CRISPR-Based Screens.
    Klein JC; Chen W; Gasperini M; Shendure J
    ACS Chem Biol; 2018 Feb; 13(2):326-332. PubMed ID: 29300083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiplexed conditional genome editing with Cas12a in
    Port F; Starostecka M; Boutros M
    Proc Natl Acad Sci U S A; 2020 Sep; 117(37):22890-22899. PubMed ID: 32843348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array.
    Zetsche B; Heidenreich M; Mohanraju P; Fedorova I; Kneppers J; DeGennaro EM; Winblad N; Choudhury SR; Abudayyeh OO; Gootenberg JS; Wu WY; Scott DA; Severinov K; van der Oost J; Zhang F
    Nat Biotechnol; 2017 Jan; 35(1):31-34. PubMed ID: 27918548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverse Class 2 CRISPR-Cas Effector Proteins for Genome Engineering Applications.
    Pyzocha NK; Chen S
    ACS Chem Biol; 2018 Feb; 13(2):347-356. PubMed ID: 29121460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted genome modification of crop plants using a CRISPR-Cas system.
    Shan Q; Wang Y; Li J; Zhang Y; Chen K; Liang Z; Zhang K; Liu J; Xi JJ; Qiu JL; Gao C
    Nat Biotechnol; 2013 Aug; 31(8):686-8. PubMed ID: 23929338
    [No Abstract]   [Full Text] [Related]  

  • 14. Could CRISPR be the solution for gene editing's Gordian knot?
    Fang H; Wang W
    Cell Biol Toxicol; 2016 Dec; 32(6):465-467. PubMed ID: 27614448
    [No Abstract]   [Full Text] [Related]  

  • 15. More specific CRISPR editing.
    de Souza N
    Nat Methods; 2014 Jul; 11(7):712. PubMed ID: 25110782
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel Type V-A CRISPR Effectors Are Active Nucleases with Expanded Targeting Capabilities.
    Aliaga Goltsman DS; Alexander LM; Devoto AE; Albers JB; Liu J; Butterfield CN; Brown CT; Thomas BC
    CRISPR J; 2020 Dec; 3(6):454-461. PubMed ID: 33146573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and applications of Type I CRISPR-Cas systems.
    Hidalgo-Cantabrana C; Barrangou R
    Biochem Soc Trans; 2020 Feb; 48(1):15-23. PubMed ID: 31922192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas3 induces broad and unidirectional genome editing in human cells.
    Morisaka H; Yoshimi K; Okuzaki Y; Gee P; Kunihiro Y; Sonpho E; Xu H; Sasakawa N; Naito Y; Nakada S; Yamamoto T; Sano S; Hotta A; Takeda J; Mashimo T
    Nat Commun; 2019 Dec; 10(1):5302. PubMed ID: 31811138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA-Targeting CRISPR-Cas Systems and Their Applications.
    Burmistrz M; Krakowski K; Krawczyk-Balska A
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Energy biotechnology in the CRISPR-Cas9 era.
    Estrela R; Cate JH
    Curr Opin Biotechnol; 2016 Apr; 38():79-84. PubMed ID: 26874259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.